Introduction
In developing countries, cervical cancer ranks second among the most common malignant tumors in women. 1 Radical hysterectomy with pelvic lymphadenectomy has been the treatment of choice for stage IA/IIB cervical cancer. Some risk factors have been identified that affect the survival of early-stage cervical cancer patients treated with radical surgery. [2] [3] [4] [5] [6] Therefore, postoperative adjuvant radiotherapy or chemoradiotherapy is recommended, depending on risk factors. Positive pelvic nodes, parametrial invasion, and positive resection margins were considered high-risk factors; submit your manuscript | www.dovepress.com
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sun et al large tumor size (LTS), deep stromal invasion (DSI), and lymphovascular space invasion (LVSI) were recognized as intermediate risk factors. [7] [8] [9] A randomized clinical trial showed that postoperative chemotherapy plus radiotherapy increased survival in high-risk patients. 10 Compared with radiation therapy (RT) alone, concurrent chemoradiotherapy (CCRT) increased the 4-year overall survival (OS) from 71% to 80% and improved the 4-year progress-free survival (PFS) from 63% to 80%. CCRT is the standard treatment recommendation for postoperative treatment for early high-risk cervical cancer. Two other randomized controlled trials have shown that, compared with no further treatment, postoperative adjuvant radiotherapy reduces local recurrence and improves PFS in intermediate-risk cervical cancer patients. 7, 11 Postoperative radiotherapy is recommended for early cervical cancer with intermediate risk factors that meet the Sedlis criteria (category 1), according to the National Comprehensive Cancer Network guidelines. However, the advantage of postoperative CCRT is not clear. Currently, there are no prospective randomized controlled clinical trials investigating the impact of CCRT for intermediate-risk patients. We were able to identify 6 retrospective studies that gave inconsistent findings. Mabuchi et al found that CCRT prolonged PFS and OS. 12 Similarly, Song et al 13 observed that CCRT prolonged recurrence-free survival (RFS) and OS for intermediate-risk patients. However, another retrospective study reported that nedaplatin CCRT improved PFS but did not increase OS compared with the RT group in patents with 2 or more risk factors. Conversely, Nakamura et al 14 reported that CCRT after radical hysterectomy did not confer benefit to intermediate-risk patients. In addition, the group who may benefit from CCRT was not clear. No standard criteria define who benefits from CCRT in cervical cancer patients with intermediate risk factors. Most previous studies analyzed the effect of CCRT on patients with various numbers of intermediate risk factors, but the relationship between the various combinations of risk factors and the efficacy of CCRT has not been analyzed.
To address these issues, we retrospectively studied the outcomes for intermediate-risk patients in our hospital to evaluate the impact of CCRT and identify the groups that might benefit from this treatment. Figure 1 . No difference was found in the pathological type and radiotherapy mode between RT-only group and the CCRT group (P.0.05). Compared with the RT-only group, the proportion of patients with a single risk factor in the CCRT group was lower, while those with 2 or 3 risk factors was higher (P,0.05). General patient characteristics are displayed in Table 1 .
Patients and methods ethics statement
radiotherapy
All patients received postoperative whole pelvic irradiation within 4-6 weeks after surgery. Pelvic radiotherapy was performed by the 4-field technique prior to 2010 and by 3-dimensional conformal radiotherapy or intensity-modulated radiotherapy after 2010. All eligible patients completed external RT, uniformly to the pelvis. The entire pelvis was irradiated with 4,500-5,400 cGy for a total of 25-28 fractions, 5 days per week. 
Follow-up
OS was defined as the time from the beginning of radiotherapy to the patient's death or the end of the final follow-up. PFS was defined as the time from the beginning of radiotherapy to metastasis or local recurrence of disease. After treatment, the patients were regularly reviewed as outpatients every 3 months in the first 2 years, every 6 months from the third to the fifth year, and every 12 months thereafter. CT with contrast of the chest and abdomen and contrast-enhanced MRI of the pelvis were performed every 6 months in the first 2 years and then yearly thereafter. Adverse effects, progression, and death were recorded. 
Results
Follow-up
The last follow-up was on December 31, 2011. Follow-up time was 6-94 months (median 61 months). A total of 18 patients were lost to follow-up, including 12 in the RTonly group and 6 in the CCRT group. The overall follow-up rate was 94.1%. In the second and the fifth year, 10 and 16 patients were lost to follow-up, respectively. These follow-up rates were 96.7% and 94.7%, respectively.
Treatment effect
At the end of the final follow-up period, a total of 20 patients died, including 15 in the RT-only group and 5 in the CCRT group. There were 22 patients with recurrence. Sites of recurrence in RT-only group were 7 local and 10 distant. Sites of recurrence in the CCRT group were 1 local and 4 distant. Table 2 displays the sites of the first recurrence and treatment regimen. Ten patients recurred in the first year, 8 in the second year, 1 in the third year, and 1 in the fourth year. Both local and distant recurrences were less frequent in patients receiving CCRT, but no statistically significant difference was found in terms of sites of recurrence between the 2 groups (P=0.160).
The 5-year OS and PFS rates of the entire cohort were 91.8% and 93.5%, respectively. The 5-year PFS in the cisplatin CCRT group was superior to that in the RT-only group (96.0% vs 89.0%, respectively; P=0.031). However, no significant difference was found in the 5-year OS between the CCRT and RT-only groups (96.0% vs 91.8%, respectively; P=0.141).
To 
Prognostic ability
Discussion
In most previous studies, risk factors such as LTS, LVSI, or DSI were regarded as "intermediate-risk factors" when 2 or more of them were present. However, in our institution, from 2008 to 2012, the indications for postoperative radiotherapy included 1 or more risk factors (ie, LVSI, depth of cervical stromal invasion .1/2, and tumor size .4 cm). Studies found that adenosquamous carcinoma histology was an intermediate-risk factor predicting recurrence. 15, 16 In our study, adenocarcinoma accounted for a higher proportion in low-or high-risk patients, and most intermediate-risk adenocarcinoma patients underwent concurrent chemotherapy with fluorouracil plus cisplatin or paclitaxel plus cisplatin regimen. Therefore, only 3 adenocarcinoma patients were eligible for this study. We did not consider the effects of pathological type on prognosis. The proportion of LTS, LVSI, and DSI in the CCRT group was significantly higher than that in RT-only group. In other words, patients in the CCRT group had worse prognostic factors. Nevertheless, survival in the CCRT group was better compared with the RT-only group. Compared with the RT-only group, CCRT reduced local and distant recurrence and improved OS and PFS. CCRT was an independent prognostic factor for favorable PFS and OS. These results suggest that CCRT significantly improves survival in some patients with poor prognosis. Our results are consistent with those of previous studies. 13, 17 No standard criteria are available to define who benefits from CCRT in cervical cancer patients with intermediate risk factors. Most previous studies examined the impact of CCRT on survival with various numbers of intermediate risk factors.
9,12-14, 18 Kim et al found that chemoradiation improved RFS in cervical cancer patients with 1 or more intermediate risk factors. 17 CCRT increased 3-year RFS in patients with 13 Japanese investigators studied nedaplatin-based CCRT for efficacy in early cervical cancer patients with 1 or more risk factors. 12, 18 Their initial findings showed that nedaplatin-based CCRT improved 3-year PFS and OS in patients with 1 or more risk factors. 12 However, with an increase in the total number of cases (from 57 to 129) and prolonged follow-up time (from 3 to 5 years), it turned out that CCRT only improved PFS in patients with 2 or 3 risk factors and showed no survival benefit in patients with only 1 risk factor. 18 Taken together, these studies indicated that the benefits of chemotherapy can be predicted to some extent, according to the number of risk factors.
The classic criteria defined intermediate-risk group as 2 or more of the following: tumor size .2 cm, LVSI, and depth of cervical stromal invasion .1/3. 2, 8, 9, 19 But the Gynecologic Oncology Group (GOG), namely, the Sedlis criteria, defined the intermediate-risk group using various combinations of 3 factors (LVSI, DSI, and tumor size). 3, 7, 19 Compared with the classic criteria, the Sedlis criteria have a more specific relationship with prognosis. The effect of CCRT on earlystage intermediate-risk cervical cancer patients is related to the number of risk factors, but it remains unclear as to the effect of CCRT in the context of combinations of risk factors. Our further subgroup analysis revealed that CCRT gave no substantial improvement of 5-year OS and PFS in patients with any 1 intermediate risk factor or 2 intermediate risk factors, including LTS and DSI. CCRT improved PFS but did not increase OS in patients with LVSI+DSI/LTS. PFS and OS in the CCRT group were superior to those in the RT-only group with 3 risk factors. Therefore, we speculate that patients with 2 or 3 intermediate risk factors, including LVSI, may potentially benefit from CCRT. In previous studies, subgroup analysis according to the number of risk factors may have hidden the effectiveness of chemotherapy because some relatively low-risk patients do not benefit from CCRT. 9, 18 In conclusion, we showed that postoperative CCRT The shortcomings of these retrospective studies may have impacted the determination of the efficacy of CCRT in intermediate-risk patients. Compared with previous studies, our study has the advantages of large sample size, identical chemotherapy regimen, and .5 years of follow-up for living patients. Nevertheless, our study suffers from the same limitations as other retrospective studies. We expect that the GOG0263 Phase III clinical findings may identify the survival benefit of CCRT for early-stage cervical cancer patients, and the groups who may benefit from CCRT.
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